Lupus & antiphospholipid syndrome
Effect of antimalarials on clinical outcomes in lupus nephritis
Authors' conclusion
The use of antimalarial drugs is associated with increased response to therapy, lower incidence of kidney flares, and lower progression to kidney failure in LN patients.
Study context
- Population
- Biopsy-proven LN patients followed for >3 years (median age 29 years; 96% female)
- Participants
- 424 patients
- Exposure
- Antimalarial users vs no users
- Outcome
- Response to therapy, incidence of LN flares and progression of kidney disease
Methodological detailstime-to-event analyses, Cox regression
- Time-to-event analyses
- Cox regression
Main finding
As reported in the abstract
Users vs No usersAdjusted hazard ratio (CI)
Complete response
1.57(1.08–2.27)
Kidney flares
0.63(0.43–0.92)
Progression to kidney failure
0.37(0.23–0.53)
Observational data: associations, not effects.
Safety
Toxic retinopathy incidence with continued antimalarial use · 3, 5 and 7 years
- By 3 years
- 1.7%
- By 5 years
- 5.7%
- By 7 years
- 8.8%
Original publication
Effect of antimalarials on clinical outcomes in lupus nephritis. Rheumatology (Oxford). Published 1 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →